Advertisement

Poxviruses pp 153-184 | Cite as

Recombinant Vaccinia Viruses As Vectors for Studying T Lymphocyte Specificity and Function

  • J. R. Bennink
  • J. W. Yewdell
Conference paper
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 163)

Abstract

Over the past 20 years, a steadily increasing portion of immunological research has been directed towards understanding the specificity and function of T lymphocytes. Vaccinia virus (VV) has proven to be the preferred vector for determining the specificity of T lymphocytes for individual gene products derived from a variety of organisms, including viruses, protozoa, and mammalian cells (we refer to these genes as “extrinsic genes”, their products as “extrinsic antigens” and their origin as “source organisms”) and for studying the processing and presentation of antigens to T lymphocytes by antigen presenting cells (APCs). The popularity of VV recombinants has two sources. First, the technology of producing VV recombinants is relatively straightforward and VV recombinants consistently provide high levels of expression of extrinsic antigens. Second, studies of T lymphocytes require the expression of antigens in histocompatible cells. The ability of VV to infect mice and a broad variety of mouse and human cell lines of diverse lineages that can function as APCs make them ideal vectors for studies of T lymphocytes.

Keywords

Major Histocompatibility Complex Influenza Virus Vaccinia Virus Major Histocompatibility Complex Molecule Vaccinia Virus Recombinant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen PM, Unanue ER (1984) Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. J Immunol 132: 1077–1079PubMedGoogle Scholar
  2. Andersson M, Paabo S, Nilsson T, Peterson PA (1985) Impaired intracellular transport of class I MHC antigen as a possible means for adenoviruses to evade immune surveillance. Cell 43: 215–222PubMedGoogle Scholar
  3. Andrew ME, Coupar BE (1988) Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol 28: 81–85PubMedGoogle Scholar
  4. Andrew ME, Coupar BE, Ada GL, Boyle DB (1986) Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microb Pathog 1: 443–452PubMedGoogle Scholar
  5. Andrew ME, Coupar BE, Boyle DB, Ada GL (1987) The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol 25: 21–28PubMedGoogle Scholar
  6. Ashman RB, Mullbacher A (1979) A T helper cell for anti-viral cytotoxic T cell responses. J Exp Med 150: 1277–1282PubMedGoogle Scholar
  7. Askonas BA, Mullbacher A, Ashman RB (1982) Cytotoxic T-memory cells in virus infection and the specificity of helper T cells. Immunology 45: 79–84PubMedGoogle Scholar
  8. Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, Sasso DR, McCormick JB (1988) Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res 9: 233–248PubMedGoogle Scholar
  9. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER (1985) Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317: 359–361PubMedGoogle Scholar
  10. Barrett T, Belsham GJ, Subbarao SM, Evans SA (1989) Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus. Virology 170: 11–18PubMedGoogle Scholar
  11. Bastin J, Rothbard J, Davey J, Jones I, Townsend A (1987) Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes. J Exp Med 168: 1935–1939Google Scholar
  12. Bennink JR, Yewdell JW (1988) Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins: high frequency of nonresponder MHC class I alleles. J Exp Med 168: 1935–1939PubMedGoogle Scholar
  13. Bennink JR, Yewdell JW, Gerhard W (1982) A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxic T-cell clone. Nature 296: 75–76PubMedGoogle Scholar
  14. Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311: 578–579PubMedGoogle Scholar
  15. Bennink JR, Yewdell JW, Smith GL, Moss B (1986) Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 57: 786–791PubMedGoogle Scholar
  16. Bennink JR, Yewdell JW, Smith GL, Moss B (1987) Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol 61: 1098–1102PubMedGoogle Scholar
  17. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panacali D (1987) Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 84: 6854–6858PubMedGoogle Scholar
  18. Berzofsky JA, Cease KB, Cornette JL, Spouge JL, Margalit H, Berkower IJ, Good MF, Miler LH, Delisi C (1987) Protein antigenic structures recognized by T cells: potential applications to vaccine design. Immunol Rev 98: 9–52PubMedGoogle Scholar
  19. Biddison WE, Sharrow SO, Shearer GM (1981) T cell subpopulations required for the human cytotoxic T lymphocyte response to influenza virus: evidence for T cell help. J Immunol 127:487–491PubMedGoogle Scholar
  20. Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC (1987a) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329: 506–512PubMedGoogle Scholar
  21. Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC (1987b) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigen. Nature 329: 512–518PubMedGoogle Scholar
  22. Blancou J, Kieny MP, Lathe R, Lecocq JP, Pastoret PP, Soulebot JP, Desmettre P (1986) Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 322: 373–375PubMedGoogle Scholar
  23. Blancou J, Artois M, Brouchier B, Thomas I, Pastoret PP, Desmettre P, Lanquet B, Kieny MP (1989) Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to fox, dog and cat. Ann Rech Vet 20: 195–204PubMedGoogle Scholar
  24. Braciale TJ (1977) Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell Immunol 33: 423–436PubMedGoogle Scholar
  25. Braciale TJ, Braciale VL, Henkle TJ, Sambrook J, Gething MJ (1984) Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer. J Exp Med 159: 341–354PubMedGoogle Scholar
  26. Braciale TJ, Braciale VL, Winkler M, Stroynowski I, Hood L, Sambrook J, Gething MJ (1987) On the role of the transmembrane anchor sequence of influenza hemagglutinin in target cell recognition by class I MHC-restricted, hemagglutinin-specific cytolytic T lymphocytes. J Exp Med 166: 678–692PubMedGoogle Scholar
  27. Braciale TJ, Sweetser MT, Morrison LA, Kittlesen DJ, Braciale VL (1989) Class I major histocompatibility complex-restricted cytolytic T lymphocytes recognize a limited number of sites on the influenza hemagglutinin. Proc Natl Acad Sci USA 86: 277–281PubMedGoogle Scholar
  28. Bray M, Zhao BT, Markoff L, Eckels KH, Chanock RM, Lai CJ (1989) Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J Virol 63: 2853–2856PubMedGoogle Scholar
  29. Brochier BM, Languet B, Blancou J, Kieny MP, Lelocq JP, Costy F, Desmettre P, Pastoret PP (1988) Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes) against rabies. Vet Microbiol 18: 103–108PubMedGoogle Scholar
  30. Brochier BM, Blancou J, Aubert MF, Kieny MP, Desmettre P, Pastoret PP (1989) Interaction between rabies infection and oral administration of vaccinia-rabies recombinant virus to foxes (Vulpes vulpes). J Gen Virol 70: 1601–1604PubMedGoogle Scholar
  31. Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC (1988) A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules [published erratum appears in Nature 333: 786] Nature 332: 845–850PubMedGoogle Scholar
  32. Burgert HG, Kvist S (1985) An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41: 987–997PubMedGoogle Scholar
  33. Burgert H-G, Maryanski JL, Kvist S (1987) “E3/19” protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci USA 84: 1356–1360PubMedGoogle Scholar
  34. Buus S, Colon S, Smith C, Freed JH, Miles C, Grey HM (1986) Interaction between a “processed” ovalbumin peptide and Ia molecules. Proc Natl Acad Sci USA 83: 3968–3971PubMedGoogle Scholar
  35. Buus S, Sette A, Colon SM, Miles C, Grey HM (1987) The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunologic peptides. Science 235: 1353–1358PubMedGoogle Scholar
  36. Cambridge G, Mackenzie JS, Keast D (1976) Cell-mediated immune response to influenza virus infections in mice. Infect Immun 13: 36–43PubMedGoogle Scholar
  37. Cantin EM, Eberle R, Baldick JL, Moss B, Willey DE, Notkins AL, Openshaw H (1987) Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci USA 84: 5908–5912PubMedGoogle Scholar
  38. Chambers TM, Kawaoka Y, Webster RG (1988) Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin. Virology 167(2): 414–421PubMedGoogle Scholar
  39. Chen BP, Parham P (1989) Direct binding of influenza peptides to class I HLA molecules. Nature 337: 743–745PubMedGoogle Scholar
  40. Clegg JC, Llyod G (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protests guinea pigs against Lassa fever. Lancet 2: 186–188PubMedGoogle Scholar
  41. Clertant P, Kieny MP, Lecocq JP, Guizani I, Chambon P, Cuzin F, Lathe R (1988) Recombinant polyoma-vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents. Biochimie 70: 1075–1087PubMedGoogle Scholar
  42. Connolly JM, Potter TA, Wormstall EM, Hansen TH (1988) The Lyt-2 molecule recognizes residues in the class I alpha-3 domain in allogeneic cytotoxic T cell responses. J Exp Med 168: 325–341.PubMedGoogle Scholar
  43. Corcoran LM, Metcalf D, Edwards SJ, Handman E (1988) GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous leishmaniasis. J Parasitol 74: 763–767PubMedGoogle Scholar
  44. Coupar BEH, Andrew ME, Both BW, Boyle DB (1986a) Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol 16: 1479–1487PubMedGoogle Scholar
  45. Coupar BEH, Andrew ME, Boyle DB, Blanden RV (1986b) Immune response to H-2Kd antigen expressed by recombinant vaccinia virus. Proc Natl Acad Sci USA 83: 7879–7882PubMedGoogle Scholar
  46. Cox JH, Yewdell JW, Eisenlohr LC, Johnson PR, Bennink JR (1990) Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 247: 715–718PubMedGoogle Scholar
  47. Cremer K, Wohlenberg C, Mackett M, Moss B, Notkins AL (1985a) Infectious vaccinia virus recombination express herpes simplex virus glycoprotein D and protect against lethal and latent infections of HSV. In: Quinnan GV (ed) Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York, pp 153–162Google Scholar
  48. Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B (1985b) Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228: 737–740PubMedGoogle Scholar
  49. De BK, Shaw MW, Rota PA, Harmon MW, Esposito JJ, Rott R, Cox NJ, Kendal AP (1988) Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus. Vaccine 6: 257–261PubMedGoogle Scholar
  50. Deubel V, Kinney RM, Esposito JJ, Cropp CB, Vorndam AV, Monath TP, Trent DW (1988) Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol 69: 1921–1929PubMedGoogle Scholar
  51. Dietzschold B, Wiktor TJ, Koprowski H (1985) Induction of virus neutralizing antibodies and protection against rabies using a vaccinia rabies glycoprotein recombinant. In: Quinnan GV (ed) Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York, pp 163–167Google Scholar
  52. Doyle C, Strominger JL (1987) Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330: 256–259PubMedGoogle Scholar
  53. Drillien R, Spehner D, Kirn A Giraudon P, Buckland R, Wild F, Lecocq J-P (1988) Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci USA 85: 1252–1256PubMedGoogle Scholar
  54. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B (1986) T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 234: 728–731PubMedGoogle Scholar
  55. Effros R, Doherty PC, Gerhard W, Bennink J (1977) Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145: 557–568PubMedGoogle Scholar
  56. Eisenlohr LC, Hackett CJ (1989) Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determination is favored by endogenous antigen synthesis. J Exp Med 169:921–931PubMedGoogle Scholar
  57. Eisenlohr LC, Gerhard W, Hackett CJ, (1987) Role of receptor-binding activity of the viral hemagglutinin molecule in the presentation of influenza virus antigens to helper T cells. J Virol 61:1375–1383PubMedGoogle Scholar
  58. Elango N, Prince GA, Murphy BR, Venkatesan S, Chanock RM, Moss B (1986) Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci USA 83: 1906–1910PubMedGoogle Scholar
  59. Ennis FA (1982) Some newly recognized aspects of resistance against and recovery from influenza. Arch Virol 73: 207–215PubMedGoogle Scholar
  60. Esposito J, Brechling K, Baer G, Moss B (1987) Vaccinia virus recombinants expressing rabies virus glycoprotein protect against rabies. Virus Genes 1: 7–21PubMedGoogle Scholar
  61. Esposito JJ, Knight JC, Shaddock JH, Novembre FJ, Baer GM (1988) Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology 165: 313–316PubMedGoogle Scholar
  62. Estin CD, Stevenson US, Plowman GD, Hu SL, Sridhar P, Hellstrom I, Brown JP, Hellstrom KE (1988) Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 85: 1052–1056PubMedGoogle Scholar
  63. Fisher-Hoch SP, McCormick JB, Auperin D, Brown BG, Castor M, Perez G, Ruo S, Conaty A, Brammer L, Bauer S (1989) Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci USA 86: 317–321PubMedGoogle Scholar
  64. Fischetti VA, Hodges WM, Hruby DE (1989) Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 244: 1487–1490PubMedGoogle Scholar
  65. Fleisher B, Becht H, Rott R (1985) Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol 135: 2800–2804Google Scholar
  66. Flexner C, Hugin A, Moss B (1987) Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330: 259–262PubMedGoogle Scholar
  67. Flexner C, Murphy BR, Rooney JF, Wohlenberg C, Yuferow V, Notkins, AL, Moss B (1988) Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature 335: 259–262PubMedGoogle Scholar
  68. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A (1987) Cytotoxic T lymphocytes recognized a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326: 881–882PubMedGoogle Scholar
  69. Gould KC, Cossins J, Bastin J, Brownlee GG, Townsend ARM (1989) A 15 amino acid fragment of influenza nucleoprotein synthesized in the cytoplasm is presented to class I-restricted cytotoxic T lymphocytes. J Exp Med 170: 1051–1056PubMedGoogle Scholar
  70. Hanlon CA, Ziemer EL, Hamir AN, Rupprecht CE (1989) Cerebrospinal fluid analysis of rabid and vaccinia-rabies glycoprotein recombinant, orally vaccinated raccoons (Procyon lotor). Ann J Vet Res 50: 364–367Google Scholar
  71. Hany M, Oehen S, Schulz M, Hengartner H, Mackett M, Hishop DHL, Overton H, Zinkernagel RM (1989) Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur J Immunol 19: 417–424PubMedGoogle Scholar
  72. Hedrick S, Germain RN, Bevan MJ Dorf M, Engel I, Fink P, Gascoigne N, Heber-Katz E, Kapp J, Kauffmann Y, Kaye J, Melchers F, Pierce C, Schwartz RH, Sorenson C, Taniguchi M, Davis MM (1985) Rearrangement and transcription of a T-cell receptor beta-chain gene in different T-cell subsets. Proc Natl Acad Sci USA 82: 531–535PubMedGoogle Scholar
  73. Hioe CE, Hinshaw VS (1989) Induction and activity of class II-restricted, Lyt-2 + cytolytic T lymphocytes specific for the influenza H5 hemagglutinin. J Immunol 142: 2482–2488PubMedGoogle Scholar
  74. Hu SL, Fultz PN, McClure HM, Eichberg JW, Thomas EK, Zarling J, Singhai MC, Kosowski SG, Swenson RB, Anderson DC, Todaro G (1987) Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 328: 721–723PubMedGoogle Scholar
  75. Hu SH, Plowman GD, Sridhar P, Stevenson US, Brown JP, Estin CD (1988) Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol 62: 176–180PubMedGoogle Scholar
  76. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO (1989) HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol 63: 1756–1762PubMedGoogle Scholar
  77. Jakeman KJ, Smith H, Sweet C (1989) Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. J Gen Virol 70: 1523–1531PubMedGoogle Scholar
  78. Jonjic S, del Val M, Keil GM, Reddehase MJ, Koszinowski UH (1988) A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 62: 1653–1658PubMedGoogle Scholar
  79. Kane KP, Vitiello A, Sherman LA, Mescher MF (1989) Cytolytic T-lymphocyte response to isolated class I H-2 proteins and influenza peptides. Nature 340: 157–159Google Scholar
  80. Kaplan DR, Griffith R, Braciale VL, Braciale TJ (1984) Influenza virus specific human cytotoxic T cell clones: heterogeneity in antigen specificity and restriction by class II products. Cell Immunol 188: 193–206Google Scholar
  81. Kees U, Krammer PH (1984) Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159: 365–377PubMedGoogle Scholar
  82. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H, Lecocq JP (1984) Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312: 163–166PubMedGoogle Scholar
  83. Kieny MP, Blancou J, Lathe R, Pastoret PP, Soulebot JP, Desmettre P, Lelocq JP (1988) Development of animal recombinant DNA vaccine and its efficacy in foxes. Rev Infect Dis [Suppl 4] 10: S799–802Google Scholar
  84. King AM, Stott EJ, Langer SJ, Young KK, Ball LA, Wertz GW (1987) Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol 61: 2885–2890Google Scholar
  85. Kinney RM, Esposito JJ, Mathews JH, Johnson BJ, Roehrig JJ, Barrett ADT, Trent DW (1988) Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol 62: 4697–4702PubMedGoogle Scholar
  86. Klein J (1986) Natural history of the major histocompatibility complex. Wiley, New YorkGoogle Scholar
  87. Klein JR, Raulet DH, Pasternack MS, Bevan MJ (1982) Cytotoxic T lymphocytes produce immune interferon in response to antigen or mitogen. J Exp Med 155: 1198-Google Scholar
  88. Koszinowski UH, Reddehase MJ, Keil GM, Volkmer H, Jonjic S, Messerle M, del Val M, Mutter W, Munch K, Buhler B (1987) Molecular analysis of herpesviral gene products recognized by protective cytotoxic T lymphocytes. Immunol Lett 16: 185–192PubMedGoogle Scholar
  89. Kotwal GJ, Moss B (1989) Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J Virol 63: 600–606PubMedGoogle Scholar
  90. Lamb RA (1989) Genes and proteins of the influenza viruses. In: Krug RM (ed) The Influenza Viruses. Plenum Press, New York, pp 1–87Google Scholar
  91. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guizani I, Cuzin F, Chambon P (1987) Tumor prevention and rejection with recombinant vaccinia. Nature 326: 878–880Google Scholar
  92. Lukacher AE, Morrison LA, Braciale VL, Malissen B, Brachiale TJ (1985) Expression of specific cytolytic activity by H-2I region-restricted influenza virus specific T lymphocyte clones. J Exp Med 162: 171–187PubMedGoogle Scholar
  93. Mackett M, and Smith GL (1986) Vaccinia virus expression vectors. J Gen Virol 67: 2067–2082PubMedGoogle Scholar
  94. Mackett M, Smith GL, Moss B (1985a) The construction and characterization of vaccinia virus recombinants expressing foreign genes. In: Glover DM (ed) DNA cloning: a practical approach, vol II. IRL, Oxford, pp 191–211Google Scholar
  95. Mackett M, Yilma T, Rose JK, Moss B (1985b) Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 227: 433–435PubMedGoogle Scholar
  96. Marchioli CC, Yancey RJ Jr, Petrovskis EA, Timmins JG, Post LE (1987) Evaluation of Pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky’s disease in mice ans swine: expression by vaccinia virus and Chinese hamster ovary cells. J Virol 61: 3977–3982PubMedGoogle Scholar
  97. Martin S, Rouse BT (1987) The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. J Immunol 138: 3431–3437PubMedGoogle Scholar
  98. Martin S, Cantin E, Rouse BT (1988) Cytotoxic T lymphocytes. Their relevance in herpesvirus infections. Ann NY Acad Sci 532: 257–272PubMedGoogle Scholar
  99. Martin S, Cantin E, Rouse BT (1989) Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins. J Gen Virol 70: 1359–1570PubMedGoogle Scholar
  100. Miller RA, Reiss CS (1984) Limiting dilution cultures reveal latent influenza virus-specific helper T cells in virus-primed mice. J Mol Cell Immunol 1: 357–368PubMedGoogle Scholar
  101. Moll H, Elchmann K, Simon MM (1985) Immunoregulation by mouse T-cell clones. II. The same H-Y-specific clones can provide help for the generation of cytotoxic lymphocytes and antibody-secreting cells. Immunology 54: 255–264PubMedGoogle Scholar
  102. Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777–785PubMedGoogle Scholar
  103. Morgan AJ, Mackett M, Finerty S, Arrand JR, Sculion FT, Epstein MA (1988) Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 25: 189–195PubMedGoogle Scholar
  104. Morris AG, Lin YL and Askonas BA (1982) Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell. Nature 295: 150–152PubMedGoogle Scholar
  105. Morrison LA, Lukacher AE, Braciale VL, Fan D, Braciale TJ (1986) Differences in antigen presentation of MHC class I and class II-restricted influenza A virus-specific cytolytic T lymphocyte clones. J Exp Med 163: 903–921PubMedGoogle Scholar
  106. Morrison RP, Earl PL, Nishio J, Lodmell DL, Moss B, Chesebro B (1987) Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature 329: 729–732PubMedGoogle Scholar
  107. Morrison HG, Bauer SP, Lange JV, Esposito JJ, McCormic JB, Auperin DD (1989) Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoprotein of Lassa virus. Virology 171: 179–188PubMedGoogle Scholar
  108. Moss B, Smith GL, Gerin JL, Purcell RH (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311: 67–69PubMedGoogle Scholar
  109. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA (1988) Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoprotein expressed by recombinant vaccinia viruses. J Virol 62: 3907–3910PubMedGoogle Scholar
  110. Nuchtern JG, Bonifacino JS, Biddison WE, Klausner RD (1989) Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature 339: 223–226PubMedGoogle Scholar
  111. Olmsted RA, Flango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock R, Collins PL (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 83: 7462–7466PubMedGoogle Scholar
  112. Olmsted RA, Buller RM, Collins PL, London WT, Beeler JA, Prince GA, Chanock RM, Murphy BR (1988) Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine 6: 519–524PubMedGoogle Scholar
  113. Olmsted RA, Murphy BR, Lawrence LA, Elango N, Moss B, Collins PL (1989) Processing surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial Virol. J Virol 63: 411–420PubMedGoogle Scholar
  114. Paabo S, Weber F, Kampe O, Schaffner W, Peterson PA (1983) Association between transplantation antigens and a viral membrane protein synthesized from a mammalian expression vector. Cell 35: 445–453Google Scholar
  115. Paabo S, Weber F, Nilsson T, Schaffner W, Peterson P (1986) Structural and functional dissection of a MHC class I antigen binding adenovirus glycoprotein. EMBO J 5: 1921–1927PubMedGoogle Scholar
  116. Paabo S, Bhat BM, Wold WSM, Peterson PA (1987) A short sequence in the COOH- terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 50: 311–317PubMedGoogle Scholar
  117. Pala P, Askonas BA (1986) Low responder MHC alleles for Tc recognition of influenza nucleoprotein. Immunogenetics 23: 379–384PubMedGoogle Scholar
  118. Pala P, Townsend ARM, Askonas BA (1986) Viral recognition by influenza A virus cross-reactive cytotoxic T (Tc) cells: the proportion of Tc cells that recognize nucleoprotein varies between individual mice. Eur J Immunol 16: 193–198PubMedGoogle Scholar
  119. Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D (1984) Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 81: 193–197PubMedGoogle Scholar
  120. Patterson RG, Lamb RA, Moss B, Murphy BR (1987) Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity. J Virol 61:1972–1977Google Scholar
  121. Paul WE (1984) Fundamental immunology. Raven, New YorkGoogle Scholar
  122. Piccini A, Paoletti E (1988) Vaccinia: virus, vector, vaccine. Adv Virus Res 34: 43–64PubMedGoogle Scholar
  123. Pickup DJ, Ink BS, Hu W, Ray CA, Joklik WK (1986) Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. Proc Natl Acad Sci USA 81: 6817–6821Google Scholar
  124. Pierce RJ, Balloul JM, Grzych JM, Dissou C, Auriault C, Boulanger D, Capron M, Soundermeyer P, Lecocq JP, Capron A (1987) GP38, P28-I and P28-II candidates for a vaccine against schistosomia. Mem Inst Oswaldo Cruz 82 [Suppl 4]: 111–114PubMedGoogle Scholar
  125. Ramshaw IA, Andrews ME, Phillips SM, Boyle DB, Coupar BEH (1987) Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329: 545–546PubMedGoogle Scholar
  126. Rawle FC, Tollefson AE, Wold WSM, Gooding LR (1989) Mouse anti-adenovirus cytotoxic T lymphocytes: inhibition of lysis by E3 gp19 K but not E3 14.7 K. Immunol 143: 2031–2037Google Scholar
  127. Reay PA, Jones IM, Gotch FM, McMichael AJ, Brownlee GG (1989) Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes. Virol 170: 477–485Google Scholar
  128. Reiss CS, Burakoff SJ (1981) Specificity of the helper T cell for the cytolytic T lymphocyte response to influenza viruses. J Exp Med 154: 541–546PubMedGoogle Scholar
  129. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL (1988) Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 62: 1530–1534PubMedGoogle Scholar
  130. Rota PA, Shaw MW, Kendal AP (1987) Comparison of the immune response to variant influenza type B hemagglutinins expressed in vaccinia virus. Virology 161: 269–275PubMedGoogle Scholar
  131. Rota PA, Shaw MW, Kendal AP (1989) Cross-protection against microvariants of influenza virus type B by vaccinia viruses expressing haemagglutinins from egg- or MDCK cell-derived subpopulations of influenza virus type B/England/222/82. J Gen Virol 70: 1533–1537PubMedGoogle Scholar
  132. Rupprecht CE, Wiktor TJ, Johnston DH, Hamir AN, Dietzschold B, Wunner WH, Glickman LT, Koprowski H (1986) Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 83: 7947–7950PubMedGoogle Scholar
  133. Rupprecht CE, Hamir AN, Johnston DH, Koprowski H (1988) Efficacy of a vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon lotor). Rev Infect Dis 10: S803–809PubMedGoogle Scholar
  134. Russell SM, Liew FY (1979) T cells primed by influenza virion internal components can cooperate in the antibody response to hemagglutinin. Nature 280: 147–148PubMedGoogle Scholar
  135. Scherle PA, Gerhard WU (1986) Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 164: 1114–1129PubMedGoogle Scholar
  136. Scherle PA, Gerhard WU (1988) Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. Proc Natl Acad Sci USA 85: 4446–4450PubMedGoogle Scholar
  137. Schwartz RH (1986) Immune response (Ir) genes of the murine major histocompatibility complex. Adv Immunol 38: 31–201PubMedGoogle Scholar
  138. Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Ito Y, Hatanaka M, Hinuma Y, Sugimoto M, Takahasi-Nishimaki F, Maruyama T, Miki K, Suzuki K, Morita M, Sashiyama H, Yoshimura N, Hayami M (1987) Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 6: 3379–3384PubMedGoogle Scholar
  139. Signas C, Katze MG, Persson H, Philipson L (1982) An adenovirus glycoprotein binds heavy chains of class I transplantation antigens from man and mouse. Nature 299: 175–178PubMedGoogle Scholar
  140. Small PA, Smith GL, Moss B (1985) Intranasal vaccination with recombinant vaccinia containing influenza hemagglutinin prevents both influenza virus pneumonia and nasal infection: intradermal vaccination prevents only viral pneumonia. In: Quinnan GV (ed) Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York, pp 175–177Google Scholar
  141. Smith GL, Murphy BR, Moss B (1983) Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 80: 7155–7159PubMedGoogle Scholar
  142. Smith GL, Levin JZ, Palese P, Moss B (1987) Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant viruses. Virology 160: 336–345PubMedGoogle Scholar
  143. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL (1987) Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 61: 3416–3423PubMedGoogle Scholar
  144. Spriggs MK, Collins PL, Tierney E, London WT, Murphy BR (1988) Immunization with vaccinia virus recombinants that express the surface glycoproteins of humans parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J Virol 62: 1293–1296PubMedGoogle Scholar
  145. Scott EJ, Ball LA, Young KK, Furze J, Wertz GW (1986) Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol 60: 607–613Google Scholar
  146. Stott EJ, Taylor G, Ball LA, Anderson K, Young KKY, King AMQ, Wertz GW (1987) Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61: 3855–3861PubMedGoogle Scholar
  147. Tanaka Y, Tevethia SS (1988) Differential effect of adenovirus 2E3/19K glycoprotein on the expression of H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis. Virology 165: 357–366PubMedGoogle Scholar
  148. Toison ND, Charlton KM, Stewart RB, Campbell JB, Wiktor TJ (1987) Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can J Vet Res 51: 363–366Google Scholar
  149. Toison ND, Charlton KM, Casey GA, Knowles MK, Rupprecht CE, Lawson KF, Campbell JB (1988) Immunization of foxes against rabies with a vaccinia recombinant virus expressing the rabies glycoprotein. Arch Virol 102: 297–301Google Scholar
  150. Townsend ARM, McMichael AJ, Carter NP, Haddleston JA, Brownlee GG (1984) Cytotoxic T cell recognition of the influenza virus nucleoprotein, hemagglutinin expressed in transfected mouse L cells. Cell 39: 13–25PubMedGoogle Scholar
  151. Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42: 457–467PubMedGoogle Scholar
  152. Townsend A, Bastin J, Gould K, Brownlee G (1986a) Cytotoxic T lymphocytes recognize influenza hemagglutinin lacking a signal sequence. Nature 324: 575–577PubMedGoogle Scholar
  153. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ (1986b) The epitopes of influenza nucleoprotein recognized by cytotpxic T lymphocytes can be defined with short peptides. Cell 44: 959–968PubMedGoogle Scholar
  154. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G (1988) Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen J Exp Med 168: 1211–1224Google Scholar
  155. Townsend ARM, Ohlen C, Bastin J, Ljunggren H, Foster L, Karre K (1989) Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340: 443–448PubMedGoogle Scholar
  156. Van Eendenburg JP, Yagello M, Girard M, Kieny MP, Lelocq JP, Muchmore E, Fultz PN, Riviere Y, Montagnier L, Gluckman JC (1989) Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res Hum Retroviruses 5:41–50PubMedGoogle Scholar
  157. Wachsman M, Aurelian L, Smith CC, Lipinskas BR, Perkus ME, Paoletti E (1987) Protection of guinea pigs form primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis 155: 1188–1197PubMedGoogle Scholar
  158. Wachsman M, Aurelian L, Hunter JC, Perkus ME, Paoletti E (1988) Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity. Biosci Rep 8: 323–334PubMedGoogle Scholar
  159. Wagner H, Starzinski-Powitz A, Jung H, Rollinghoff M (19877) Induction of I-region restricted hapten-specific cytotoxic T lymphocytes. J Immunol 119: 1365–1368Google Scholar
  160. Watts TH, Brian AA, Kappler J, Marrack P, McConnel HM, (1984;) Antigen presentation by supported planar membranes containing affinity-purified I-Ad. Proc Natl Acad Sci USA 81:7564–7568Google Scholar
  161. Webster RG, Reay PA, Laver WG (1988) Protection against lethal influenza with neuraminidase. Virology 164: 230–237PubMedGoogle Scholar
  162. Weiss S, Bogen B (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 86: 282–286Google Scholar
  163. Wertz GW, Stott EJ, Young KK, Anderson K, Ball LA (1987) Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol 61: 293–301PubMedGoogle Scholar
  164. Whitton JL, Oldstone MBA (1989) Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med 170: 1033–1038PubMedGoogle Scholar
  165. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis P, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M, Moss B, Koprowski H (1984) Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 81: 7194–7198PubMedGoogle Scholar
  166. Willey DE, Cantin EM, Hill LR, Moss B, Notkins AL, Openshaw H (1988) Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection. J Infect Dis 158: 1382–1386PubMedGoogle Scholar
  167. Wold WS, Cladaras C, Deutscher, SL, Kapoor QS (1985) The 19 kDa glycoprotein coded by region E3 of adenovirus. J Biol Chem 260: 2421–2431Google Scholar
  168. Wysocka M, Bennink JR (1988) Limiting dilution analysis of memory cytotoxic T lymphocyte specific for individual influenza virus gene products. Cell Immunol 112: 425–429PubMedGoogle Scholar
  169. Wysocka M, Hackett CJ (1990) Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype NI. J Virol 64: 1028–1030PubMedGoogle Scholar
  170. Yewdell JW, Bennink JR (1989) Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 244: 1072–1075PubMedGoogle Scholar
  171. Yewdell JW, Hackett CJ (1989) The specificity and function of T lymphocytes induced by influenza A viruses. In: Krug R (ed) The influenza viruses, Plenum, New York.Google Scholar
  172. Yewdell JW, Bennink JR, Smith GL Moss B (1985) Influenza A virus nucleoprotein is a major target antigen for crossreactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 1785–1789PubMedGoogle Scholar
  173. Yewdell JW, Bennink JR, Mackett M, Lefrancois L, Lyles DS, Moss B (1986) Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes. J Exp Med 163: 1529–1538PubMedGoogle Scholar
  174. Yewdell JW, Bennink JR, Hosaka Y (1988) Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239: 637–640PubMedGoogle Scholar
  175. Yilma T, Hsu D, Jones L, Owens S, Grubman M, Mebus C, Yamanaka M, Dale B (1988) Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 242: 1058–1061PubMedGoogle Scholar
  176. Zinkernagel RM, Doherty PC (1979) MHC-restricted cytotoxic T cells. Adv Immunol 27: 51–77PubMedGoogle Scholar
  177. Zweerink HJ, Courtneidge SA, Skehel JJ, Crumpton MJ, Askonas BA (1977) Cytotoxic T cells kill influenza virus infected cells but do not distinguished between serologically distinct type A viruses. Nature 267: 354–356PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1990

Authors and Affiliations

  • J. R. Bennink
    • 1
  • J. W. Yewdell
    • 1
  1. 1.Laboratory of Viral DiseasesNIAIDRockvilleUSA

Personalised recommendations